← All candidates
One insider buy in the last year — $1.65M in all.
15 filings on record.
IDYAIDEAYA Biosciences, Inc.
NasdaqGS · Healthcare · $3.56B
$37.66
-0.97% · Sep 15
One insider buy in the last year — $1.65M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy◆ 10 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$3.56B
Float
87.1M
90% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
15.8
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Stein Jeffrey
Bought $1.65M on Mar 2 — 50,000 sh @ $32.96, held direct, 92% of their stake.
No completed positions to measure
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
Context
Wall St
$52.29 avg target
+38.8% vs today · 14 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$1.11 act−$0.13
Q4 '25−$0.94 act+$0.01
Q3 '25$1.33 act+$1.88
Q2 '25−$0.88 act−$0.09
Coverage
Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy StudyInsider Monkey · 06-11What IDEAYA Biosciences (IDYA)'s Darovasertib Phase 2/3 Win and Roche Deal Mean For ShareholdersSimply Wall St. · 06-06IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology SummitMarketBeat · 05-26
The file stays open
15 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice